A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan; and an additive selected from the group consisting of a hydration promoter, a particle adhesion inhibitor, a particle aggregation inhibitor, and combinations thereof. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.

The present disclosure relates to method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose, the method comprising providing a hydrogel comprising nanofibrillar cellulose, providing cell-free tissue extract comprising a mixture of bioactive substances, providing polyethylene glycol, providing trehalose, mixing the hydrogel, the cell-free tissue extract, the polyethylene glycol and the trehalose to obtain a mixture, and freeze drying the mixture to obtain a cell-free tissue extract in the dried hydrogel comprising nanofibrillar cellulose. The present disclosure relates to a dried hydrogel comprising nanofibrillar cellulose, cell-free tissue extract comprising a mixture of bioactive substances, polyethylene glycol and trehalose, wherein the moisture content of the dried hydrogel is 10% (w/w) or less.

The present invention relates to hemostatic scaffold compositions and the method of preparation thereof. In present invention, hemostatic scaffold compositions for wound care and dental care, uses chitosan and tranexamic acid.

The present invention provides an artificial dressing and a use of the artificial dressing for promoting wound healing. The artificial dressing includes a gelatin and a fungal extract.

The subject of the present invention is a composite wound packing material comprising a casing enclosing a material, or an assembly of materials, forming fluid flow channels, said casing being composed of a self-supporting interface material formed from a thin layer of a composition comprising a hydrophobic matrix and comprising through-holes, said hydrophobic matrix comprising, per 100 parts by weight of a styrene/saturated olefin/styrene triblock copolymer having a viscosity of between 0.2 and 2 Pa.Math.s, as measured in a 10% (weight/weight) solution in toluene, from 400 to 1220 parts by weight of a plasticizer, preferably a plasticizing oil, and from 0 to 720 parts by weight of petroleum jelly, it being specified, moreover, that the total amount of plasticizer and petroleum jelly is greater than or equal to 750 parts by weight and the amount of petroleum jelly is between 400 and 720 parts by weight when the amount of plasticizer is between 1000 and 1220 parts by weight.

The present invention relates to a topical dressing composition for the treatment of damaged skin tissue in a subject, wherein said topical dressing comprises mesenchymal stem cells embedded in a topical matrix. Particularly the invention relates to a storage-stable topical dressing composition for the treatment of damaged skin tissue in a subject, wherein said topical dressing comprises up to about 40,000 mesenchymal stem cells per square centimetre embedded in a topical matrix and, optionally a pharmaceutically acceptable excipient.

The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of said formulation to said ulcer; followed by (b) application of a dressing, and wherein said application of said formulation provides for a dose of LL-37 at the wound site that is below about 80 g of LL-37 applied per cm2 of wound area, and/or below about 26.7 g of LL-37 applied per cm.sup.2 of wound area, per day of treatment.

Disclosed herein is a pressurized therapeutic composition configured to be stored in a valved container designed to maintain an inverse thermosensitive polymer foam composition under pressure and dispense the composition upon opening the valve thereof. After the composition is dispensed from the container the evaporation of an expanding component (e.g., compressed gas or volatile liquid) can cause the inverse thermosensitive polymer solution to foam. The reduced pressure produced from dispensing the inverse thermosensitive polymer solution can reduce its temperature so as to facilitate distribution in a more liquid foam form. The inverse thermosensitive polymer solution can undergo a reverse phase change from a liquid to a gel upon warming (e.g., once dispensed onto or into a body part).

Wound dressing compositions comprising of a bioresorbable sponge encapsulated within a polysaccharide envelope. The bioresorbable sponge is preferably comprised of collagen and oxidised regenerated cellulose. The outer polysaccharide envelope is preferably comprised of chitosan. The outer polysaccharide envelope functions to modulate the rate at which the bioresorable sponge breaks down within a wound.

The invention discloses a pharmaceutical hemostatic liquid foam base preparation comprising albumin as foaming agent and a fibrinogen precipitating substance and optionally a coagulation inducing agent, wherein albumin as foaming agent is present in native form; a method for the production of a transient hemostatic liquid foam; the transient hemostatic liquid foam; and a kit for making the foam.